Reported 2 months ago
Pfizer's recent decision to advance its weight loss drug candidate, danuglipron, could pose a challenge to Eli Lilly, which currently leads the market with its successful drugs Mounjaro and Zepbound. Despite the competition, Lilly has several advantages including established market presence and ongoing trials for additional weight loss drugs that position it favorably in a growing $100 billion market space. Even with Pfizer aiming to launch a similar product, Lilly's established track record suggests it may continue to thrive.
Source: YAHOO